This HTML5 document contains 77 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n21http://linked.opendata.cz/resource/drugbank/drug/DB01177/identifier/drugbank/
n28http://linked.opendata.cz/resource/AHFS/
n14http://linked.opendata.cz/resource/drugbank/company/
n18http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n19http://linked.opendata.cz/resource/drugbank/drug/DB01177/identifier/national-drug-code-directory/
n10http://linked.opendata.cz/resource/drugbank/dosage/
n23http://linked.opendata.cz/resource/drugbank/drug/DB01177/identifier/chemspider/
n4http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n22http://linked.opendata.cz/resource/drugbank/drug/DB01177/identifier/chebi/
n26http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n24http://linked.opendata.cz/resource/drugbank/drug/DB01177/identifier/wikipedia/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n13http://linked.opendata.cz/resource/drugbank/medicinal-product/
n5http://linked.opendata.cz/ontology/drugbank/
n17http://linked.opendata.cz/ontology/mesh/
n25http://linked.opendata.cz/resource/drugbank/drug/DB01177/identifier/pharmgkb/
owlhttp://www.w3.org/2002/07/owl#
n12http://www.drugs.com/cdi/
n27http://www.rxlist.com/cgi/generic2/
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n20http://linked.opendata.cz/resource/drugbank/drug/DB01177/identifier/pubchem-compound/
n9http://linked.opendata.cz/resource/atc/
n16http://linked.opendata.cz/resource/drugbank/drug/DB01177/identifier/pubchem-substance/
n8http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01177
rdf:type
n5:Drug
n5:description
An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. [PubChem]
n5:dosage
n10:271B4F51-363D-11E5-9242-09173F13E4C5 n10:271B4F52-363D-11E5-9242-09173F13E4C5 n10:271B4F4D-363D-11E5-9242-09173F13E4C5 n10:271B4F4E-363D-11E5-9242-09173F13E4C5 n10:271B4F4F-363D-11E5-9242-09173F13E4C5 n10:271B4F50-363D-11E5-9242-09173F13E4C5
n5:group
approved
n5:halfLife
22 hours
n5:indication
For the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7.
owl:sameAs
n4:DB01177 n26:DB01177
dcterms:title
Idarubicin
adms:identifier
n16:46506973 n19:0013-2526-86 n20:42890 n21:DB01177 n22:42068 n23:39117 n24:Idarubicin n25:PA449961
n5:mechanismOfAction
Idarubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: Idarubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes.
n5:packager
n14:271B4F47-363D-11E5-9242-09173F13E4C5 n14:271B4F4A-363D-11E5-9242-09173F13E4C5 n14:271B4F4B-363D-11E5-9242-09173F13E4C5 n14:271B4F48-363D-11E5-9242-09173F13E4C5 n14:271B4F49-363D-11E5-9242-09173F13E4C5 n14:271B4F46-363D-11E5-9242-09173F13E4C5
n5:routeOfElimination
The drug is eliminated predominately by biliary and to a lesser extent by renal excretion, mostly in the form of idarubicinol.
n5:synonym
Idarubicina (1S,3S)-3-Acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside Idarubicine 4-Demethoxydaunomycin 5,12-Naphthacenedione, 9-acetyl-7-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-, (7S-cis)- 4-Demethoxydaunorubicin Idarubicinum
n8:hasAHFSCode
n28:10-00-00
n5:proteinBinding
97%
n5:salt
n5:synthesisReference
Marco Villa, Roberto Arosio, Roberta Fretta, Nicola Diulgheroff, "Synthesis of idarubicin aglycone." U.S. Patent US20060047108, issued March 02, 2006.
n17:hasConcept
n18:M0023493
foaf:page
n12:idarubicin.html n27:idarubicin.htm
n5:IUPAC-Name
n6:271B4F57-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B4F5D-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B4F5C-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B4F59-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B4F5A-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B4F5B-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B4F55-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B4F6D-363D-11E5-9242-09173F13E4C5 n6:271B4F53-363D-11E5-9242-09173F13E4C5 n6:271B4F56-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B4F54-363D-11E5-9242-09173F13E4C5
n8:hasATCCode
n9:L01DB06
n5:H-Bond-Acceptor-Count
n6:271B4F63-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B4F64-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B4F5E-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B4F5F-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B4F61-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B4F60-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B4F62-363D-11E5-9242-09173F13E4C5
n5:affectedOrganism
Bacteria Humans and other mammals
n5:casRegistryNumber
58957-92-9
n5:category
n5:containedIn
n13:271B4F4C-363D-11E5-9242-09173F13E4C5
n5:Bioavailability
n6:271B4F69-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B4F6B-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B4F6C-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B4F68-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B4F67-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B4F6A-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B4F58-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B4F65-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B4F66-363D-11E5-9242-09173F13E4C5